Last reviewed · How we verify
18F-MFBG
18F-MFBG is a fluorine-18 labeled radiopharmaceutical that targets norepinephrine transporters for positron emission tomography (PET) imaging of neuroendocrine tumors.
18F-MFBG is a fluorine-18 labeled radiopharmaceutical that targets norepinephrine transporters for positron emission tomography (PET) imaging of neuroendocrine tumors. Used for Imaging of neuroendocrine tumors including pheochromocytoma and paraganglioma, Neuroblastoma imaging and staging.
At a glance
| Generic name | 18F-MFBG |
|---|---|
| Also known as | Florbenguane F-18, meta-fluorobenzylguanidine, IRP101, 18F-metafluorobenzylguanidine |
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Drug class | PET imaging agent / Radiopharmaceutical |
| Target | Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Oncology / Nuclear Medicine |
| Phase | Phase 3 |
Mechanism of action
18F-MFBG is a PET imaging agent that mimics norepinephrine and binds to norepinephrine transporters (NET) expressed on neuroendocrine tumor cells. This allows visualization and localization of NET-positive tumors such as pheochromocytoma, paraganglioma, and neuroblastoma. The fluorine-18 radiolabel enables high-resolution PET imaging for diagnostic and staging purposes.
Approved indications
- Imaging of neuroendocrine tumors including pheochromocytoma and paraganglioma
- Neuroblastoma imaging and staging
Common side effects
Key clinical trials
- 18F-mFBG Cardiac Uptake With Lewy Body Dementia (PHASE2)
- 18F-mFBG Imaging for Myocardial Sympathetic Innervation (PHASE2)
- Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma (PHASE2)
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
- Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma. (PHASE2)
- 18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
- 18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
- Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |